These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30885221)

  • 21. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
    Berthold HK; Unverdorben S; Degenhardt R; Bulitta M; Gouni-Berthold I
    JAMA; 2006 May; 295(19):2262-9. PubMed ID: 16705107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects.
    Cicero AF; Derosa G; Parini A; Maffioli P; D'Addato S; Reggi A; Giovannini M; Borghi C
    Nutr Res; 2013 Aug; 33(8):622-8. PubMed ID: 23890351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia.
    Bradford RH; Shear CL; Chremos AN; Dujovne C; Franklin FA; Hesney M; Higgins J; Langendörfer A; Pool JL; Schnaper H
    Am J Cardiol; 1990 Sep; 66(8):44B-55B. PubMed ID: 2206036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.
    Cubeddu LX; Cubeddu RJ; Heimowitz T; Restrepo B; Lamas GA; Weinberg GB
    Am Heart J; 2006 Nov; 152(5):982.e1-5. PubMed ID: 17070175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials.
    Millán J; Cicero AF; Torres F; Anguera A
    Clin Investig Arterioscler; 2016; 28(4):178-87. PubMed ID: 27131395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
    Affuso F; Ruvolo A; Micillo F; Saccà L; Fazio S
    Nutr Metab Cardiovasc Dis; 2010 Nov; 20(9):656-61. PubMed ID: 19699071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
    Hodis HN; Mack WJ; Azen SP; Alaupovic P; Pogoda JM; LaBree L; Hemphill LC; Kramsch DM; Blankenhorn DH
    Circulation; 1994 Jul; 90(1):42-9. PubMed ID: 8026027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single blind, multicentre, randomized, controlled trial testing the effects of a novel nutraceutical compound on plasma lipid and cardiovascular risk factors: Results of the interim analysis.
    Trimarco V; Battistoni A; Tocci G; Coluccia R; Manzi MV; Izzo R; Volpe M
    Nutr Metab Cardiovasc Dis; 2017 Oct; 27(10):850-857. PubMed ID: 28965797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.
    Kerzner B; Corbelli J; Sharp S; Lipka LJ; Melani L; LeBeaut A; Suresh R; Mukhopadhyay P; Veltri EP;
    Am J Cardiol; 2003 Feb; 91(4):418-24. PubMed ID: 12586255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
    Castaño G; Mas R; Fernández L; Illnait J; Gámez R; Alvarez E
    Int J Clin Pharmacol Res; 2001; 21(1):43-57. PubMed ID: 11708574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial.
    Derosa G; D'Angelo A; Romano D; Maffioli P
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, Double-Blind, Placebo-Controlled Trial to Test the Effects of a Nutraceutical Combination Monacolin K-Free on the Lipid and Inflammatory Profile of Subjects with Hypercholesterolemia.
    Protic O; Di Pillo R; Montesanto A; Galeazzi R; Matacchione G; Giuliani A; Sabbatinelli J; Gurău F; Silvestrini A; Olivieri F; Antonicelli R; Bonfigli AR
    Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
    J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A placebo-controlled trial of a proprietary lipid-lowering nutraceutical supplement in the management of dyslipidemia.
    Houston M; Rountree R; Lamb J; Phipps S; Meng S; Zhang B
    J Biol Regul Homeost Agents; 2016; 30(4):1115-1123. PubMed ID: 28078862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of treatment with monacolin K, berberine and coenzyme Q10 on lipid metabolism in patients with moderate cardiovascular risk.
    Martinez-Martin F; Corbella E; Sarasa I; Trias F; Petitbò D; Licerán M; Sánchez-Hernández RM; Martin D; Sánchez A; Arnás C; de Dios S; Florido M; Pintó X
    Semergen; 2022 Sep; 48(6):403-410. PubMed ID: 35606250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.